

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 October 2023 (12.10.2023)



(10) International Publication Number
WO 2023/194915 A1

(51) International Patent Classification:
A61K 39/00 (2006.01) *A61P 35/00* (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/IB2023/053435

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:
04 April 2023 (04.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/327,230 04 April 2022 (04.04.2022) US
63/371,860 18 August 2022 (18.08.2022) US
63/482,755 01 February 2023 (01.02.2023) US

(71) Applicant: **GAMMADELTA THERAPEUTICS LTD**
[GB/GB]; 1 Kingdom Street, London W2 6BD (GB).

(72) Inventors: **KOVACS, Istvan**; c/o GAMMADELTA THERAPEUTICS LTD, 1 Kingdom Street, London W2 6BD (GB). **SIMOES, Andre Goncalo do Espirito Santo**; c/o GAMMADELTA THERAPEUTICS LTD, 1 Kingdom Street, London W2 6BD (GB). **ILLINGWORTH, Samuel**; c/o GAMMADELTA THERAPEUTICS LTD, 1 Kingdom Street, London W2 6BD (GB). **KUMARAN, Jyothi**; c/o GAMMADELTA THERAPEUTICS LTD, 1 Kingdom Street, London W2 6BD (GB). **NUSSBAUMER, Oliver**; c/o GAMMADELTA THERAPEUTICS LTD, 1 Kingdom Street, London W2 6BD (GB). **KARATTIL, Rajeev**; c/o GAMMADELTA THERAPEUTICS LTD, 1 Kingdom Street, London W2 6BD (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: NOVEL GENE ARMORING

(57) Abstract: The present disclosure provides compositions and methods for engineering $\gamma\delta$ T cells (e.g., $\nu\delta 1$ T cells and $\nu\delta 2$ T cells) with an IL-15 receptor β subunit (IL-15R β), e.g., by transduction with a viral vector, to restore IL-15 responsiveness. Further provided are populations of engineered $\gamma\delta$ T cells and methods of using the same.

WO 2023/194915 A1